ArticleMolecular pharmaceutics2017

Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.

John S Schardt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.